Suchergebnisse - "Polyethylene Glycols adverse effects"

Adverse Impacts of PEGylated Protein Therapeutics: A Targeted Literature Review

Autoren: Chae Sung Lee Yogesh Kulkarni Vicki Pierre et al.

Quelle: BioDrugs

Schlagwörter: ddc:610, Humans, Proteins, Review Article, Polyethylene Glycols/adverse effects [MeSH], Humans [MeSH], Proteins/therapeutic use [MeSH], Proteins/administration, Proteins/adverse effects [MeSH], Polyethylene Glycols

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39417964
https://repository.publisso.de/resource/frl:6518454
https://opus.bibliothek.uni-wuerzburg.de/files/39745/40259_2024_Article_684.pdf
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/39745
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-397452
https://doi.org/10.1007/s40259-024-00684-z

Diarrhoeal events can trigger long-term Clostridium difficile colonization with recurrent blooms

Autoren: David VanInsberghe Joseph Elsherbini Bernard J. Varian et al.

Quelle: Nature Microbiology. 5:642-650

Schlagwörter: Male, 0301 basic medicine, Feces/microbiology, IMPACT, Colony Count, Colony Count, Microbial, Fusobacteria/genetics, Polyethylene Glycols/adverse effects, Laxatives/adverse effects, DISEASE, Polyethylene Glycols, Feces, Mice, Clostridium difficile/drug effects, Microbial, RNA, Ribosomal, 16S, INFECTION, Gastrointestinal Microbiome/drug effects, Clostridium Infections/complications, HUMAN MICROBIOME, 2. Zero hunger, 106022 Mikrobiologie, 0303 health sciences, GUT MICROBIOTA, Bacteroidetes/genetics, 3. Good health, Actinobacteria, ALIGNMENT, Laxatives, SDG 3 – Gesundheit und Wohlergehen, 106022 Microbiology, Diarrhea/chemically induced, 16S/genetics, Diarrhea, TRANSMISSION, Firmicutes, Fusobacteria, 03 medical and health sciences, SDG 3 - Good Health and Well-being, EPIDEMIC, Proteobacteria, Animals, Humans, Actinobacteria/genetics, Ribosomal, Animal, Bacteroidetes, Clostridioides difficile, Gastrointestinal Microbiome, Disease Models, Animal, Disease Models, RISK-FACTORS, Clostridium Infections, RNA, Firmicutes/genetics, Proteobacteria/genetics

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/32042128
https://ucrisportal.univie.ac.at/de/publications/7442a338-6e17-47bc-a0c2-bf1a5931f717
https://doi.org/10.1038/s41564-020-0668-2
https://europepmc.org/article/MED/32042128
https://www.ncbi.nlm.nih.gov/pubmed/32042128
https://www.nature.com/articles/s41564-020-0668-2
https://www.nature.com/articles/s41564-020-0668-2.pdf

Magnesium hydroxide versus macrogol/electrolytes in the prevention of opioid-induced constipation in incurable cancer patients: study protocol for an open-label, randomized controlled trial (the OMAMA study): study protocol for an open-label, randomized controlled trial (the OMAMA study)

Autoren: Kistemaker, K R J de Graeff, Alexander Crul, M et al.

Weitere Verfasser: Kistemaker, K R J de Graeff, Alexander Crul, M et al.

Quelle: BMC Palliat Care
BMC Palliative Care, Vol 22, Iss 1, Pp 1-8 (2023)
Kistemaker, K R J, de Graeff, A, Crul, M, de Klerk, G, van de Ven, P M, van der Meulen, M P, van Zuylen, L & Steegers, M A H 2023, 'Magnesium hydroxide versus macrogol/electrolytes in the prevention of opioid-induced constipation in incurable cancer patients : study protocol for an open-label, randomized controlled trial (the OMAMA study)', BMC Palliative Care, vol. 22, no. 1, 22, pp. 22. https://doi.org/10.1186/s12904-023-01143-2

Schlagwörter: Magnesium Hydroxide, Macrogol/electrolytes, Constipation/chemically induced, Polyethylene Glycols/adverse effects, Laxatives/therapeutic use, Polyethylene Glycols, Magnesium hydroxide, Study Protocol, Neoplasms, Journal Article, Humans, Multicenter Studies as Topic, Neoplasms/complications, Cancer, Randomized Controlled Trials as Topic, Analgesics, Analgesics, Opioid/adverse effects, RC952-1245, General Medicine, 3. Good health, Clinical trial, Opioids, Analgesics, Opioid, Magnesium Hydroxide/adverse effects, Laxative, Special situations and conditions, Laxatives, Palliative care, Quality of Life, Opioid-Induced Constipation/drug therapy, Opioid/adverse effects, Constipation, Opioid-Induced Constipation

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/36915062
https://doaj.org/article/de0de4c54a1b4e40af42b66a1e021371
https://research.vumc.nl/en/publications/9d888f6e-627f-42a0-a181-2d0b28022877
https://dspace.library.uu.nl/handle/1874/448809
https://pure.amsterdamumc.nl/en/publications/9943f27e-7056-4262-afeb-3e96c07593ba
https://doi.org/10.1186/s12904-023-01143-2

ROP-ET: A Prospective Phase III Trial Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythemia Patients with Limited Treatment Options

Autoren: Kiladjian, Jean-Jacques Marin, Francisca Ferrer Al-Ali, Haifa Kathrin et al.

Quelle: Ann Hematol
Annals of Hematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
Institut de Recerca Germans Trias i Pujol (IGTP)
Blood
Ann Hematol 103(7), 2299-2310 (2024). doi:10.1007/s00277-024-05665-4

Schlagwörter: Adult, Male, 0301 basic medicine, essential thrombocythemia (ET), Aged [MeSH], Interferon alpha-2/therapeutic use [MeSH], Phase III, Essential thrombocythemia (ET), Myeloproliferative neoplasms (MPNs), Clinical Trials, Phase III as Topic [MeSH], Recombinant Proteins/adverse effects [MeSH], Male [MeSH], Polyethylene Glycols/therapeutic use [MeSH], Female [MeSH], Ropeginterferon alfa-2b, Interferon-alpha/therapeutic use [MeSH], Adult [MeSH], Interferon-alpha/adverse effects [MeSH], Humans [MeSH], Prospective Studies [MeSH], Treatment Outcome [MeSH], Middle Aged [MeSH], Multicenter Studies as Topic [MeSH], Recombinant Proteins/administration, Polyethylene Glycols/adverse effects [MeSH], Recombinant Proteins/therapeutic use [MeSH], Thrombocythemia, Essential/drug therapy [MeSH], Polyethylene Glycols/administration, Research, ROP-ET, Interferon alpha-2/adverse effects [MeSH], Disease modification, Interferon alpha-2, Polyethylene Glycols, 03 medical and health sciences, Humans, Multicenter Studies as Topic, ropeginterferon alfa-2b, Prospective Studies, Aged, 0303 health sciences, disease modification, Interferon-alpha, Middle Aged, phase III, Recombinant Proteins, 3. Good health, Treatment Outcome, Clinical Trials, Phase III as Topic, Female, Thrombocythemia, Essential

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38438627
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14921
https://fundanet.igtp.cat/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=14343
https://ddd.uab.cat/record/302147
https://pergamos.lib.uoa.gr/uoa/dl/object/3483688
https://ruj.uj.edu.pl/handle/item/343050
https://link.springer.com/article/10.1007/s00277-024-05665-4
https://repository.publisso.de/resource/frl:6524348
https://publications.rwth-aachen.de/record/1008089

Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.

Autoren: Gonvers, J.J. Heim, M.H. Cavassini, M. et al.

Schlagwörter: AIDS-Related Opportunistic Infections/drug therapy, Adult, Antiretroviral Therapy, Highly Active, Antiviral Agents/adverse effects, Antiviral Agents/therapeutic use, Drug Administration Schedule, Drug Therapy, Combination, Female, Genotype, HIV Infections/drug therapy, HIV Infections/virology, Hepacivirus/drug effects, Hepacivirus/genetics, Hepatitis C, Chronic/drug therapy, Chronic/virology, Humans, Interferon Alfa-2a/adverse effects, Interferon Alfa-2a/therapeutic use, Long-Term Care, Male, Middle Aged, Polyethylene Glycols/adverse effects, Polyethylene Glycols/therapeutic use, RNA, Viral/blood, Ribavirin/adverse effects, Ribavirin/therapeutic use

Dateibeschreibung: application/pdf

Relation: Swiss Medical Weekly; 1424-3997[electronic], 0036-7672[linking]; https://iris.unil.ch/handle/iris/92351; serval:BIB_54956A129E71; 000289450100001

Verfügbarkeit: https://iris.unil.ch/handle/iris/92351
https://doi.org/10.4414/smw.2010.13055

Myocardial infarction after ultrasoundguided foam sclerotherapy for varicose veins--a case report and review of the literature of a rare but serious adverse event.

Autoren: Engelberger, R.P. Ney, B. Clair, M. et al.

Schlagwörter: Aged, Anticoagulants/therapeutic use, Humans, Injections, Intravenous, Male, Myocardial Infarction/diagnosis, Myocardial Infarction/drug therapy, Polyethylene Glycols/administration & dosage, Polyethylene Glycols/adverse effects, Risk Factors, Sclerosing Solutions/administration & dosage, Sclerosing Solutions/adverse effects, Sclerotherapy/adverse effects, Treatment Outcome, Ultrasonography, Interventional, Varicose Veins/diagnosis, Varicose Veins/therapy

Relation: Vasa. Zeitschrift Für Gefässkrankheiten; https://iris.unil.ch/handle/iris/72414; serval:BIB_27F916684E95; 000375874300011

Verfügbarkeit: https://iris.unil.ch/handle/iris/72414
https://doi.org/10.1024/0301-1526/a000534

Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.

Autoren: Schoepfer, A.M. Vavricka, S.R. Binek, J. et al.

Weitere Verfasser: Schoepfer, A.M. Vavricka, S.R. Binek, J. et al.

Schlagwörter: Adrenal Cortex Hormones/therapeutic use, Adult, Aged, Antibodies, Monoclonal/therapeutic use, Monoclonal, Humanized, Crohn Disease/drug therapy, Female, Humans, Immunoglobulin Fab Fragments/adverse effects, Immunoglobulin Fab Fragments/therapeutic use, Immunologic Factors/therapeutic use, Male, Middle Aged, Polyethylene Glycols/adverse effects, Polyethylene Glycols/therapeutic use, Prospective Studies, Questionnaires, Rectal Fistula/drug therapy, Switzerland%22">Type="Geographic">Switzerland, Treatment Outcome, Tumor Necrosis Factor-alpha/antagonists &, inhibitors, Young Adult

Relation: Inflammatory Bowel Diseases; https://iris.unil.ch/handle/iris/34302; serval:BIB_06FA0455E3EE; 000278514100009

Verfügbarkeit: https://iris.unil.ch/handle/iris/34302
https://doi.org/10.1002/ibd.21127

Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).

Autoren: Templeton, A.J. Ribi, K. Surber, C. et al.

Weitere Verfasser: Templeton, A.J. Ribi, K. Surber, C. et al.

Schlagwörter: Administration, Topical, Aged, Aluminum Hydroxide/pharmacology, Aluminum Hydroxide/therapeutic use, Antiperspirants/pharmacology, Antiperspirants/therapeutic use, Breast Neoplasms/drug therapy, Breast Neoplasms/pathology, Chlorides/pharmacology, Chlorides/therapeutic use, Double-Blind Method, Doxorubicin/administration & dosage, Doxorubicin/adverse effects, Drug Monitoring/methods, Female, Hand-Foot Syndrome/prevention & control, Humans, Middle Aged, Neoplasm Staging, Polyethylene Glycols/administration & dosage, Polyethylene Glycols/adverse effects, Severity of Illness Index, Skin Cream, Treatment Outcome

Relation: The Breast; https://iris.unil.ch/handle/iris/219367; serval:BIB_90D8595437E8; 000335509600007

Verfügbarkeit: https://iris.unil.ch/handle/iris/219367
https://doi.org/10.1016/j.breast.2014.02.005

Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study.

Autoren: Mitsunaga, K. Bagot, M. Ram-Wolff, C. et al.

Schlagwörter: Humans, Mycosis Fungoides/drug therapy, Mycosis Fungoides/pathology, Middle Aged, Female, Male, Interferon-alpha/administration & dosage, Interferon-alpha/adverse effects, Interferon-alpha/therapeutic use, Recombinant Proteins/administration & dosage, Recombinant Proteins/adverse effects, Retrospective Studies, Skin Neoplasms/drug therapy, Skin Neoplasms/pathology, Polyethylene Glycols/administration & dosage, Polyethylene Glycols/adverse effects, Aged, Sezary Syndrome/drug therapy, Sezary Syndrome/pathology, Treatment Outcome, Adult, Time Factors, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use

Relation: British Journal of Dermatology; https://iris.unil.ch/handle/iris/194372; serval:BIB_7FA3BAF6F879; 001233567900001

Verfügbarkeit: https://iris.unil.ch/handle/iris/194372
https://doi.org/10.1093/bjd/ljae152

Polyethylene Glycol Drug-Eluting Embolic Microspheres Loaded with Doxorubicin for the Treatment of Hepatocellular Carcinoma: Feasibility, Safety, and Pharmacokinetic Study.

Autoren: Malagari, K. Denys, A. Burrel, M. et al.

Schlagwörter: Antibiotics, Antineoplastic/adverse effects, Carcinoma, Hepatocellular/diagnostic imaging, Hepatocellular/drug therapy, Hepatocellular/pathology, Chemoembolization, Therapeutic/adverse effects, Doxorubicin/adverse effects, Feasibility Studies, Female, Humans, Liver Neoplasms/diagnostic imaging, Liver Neoplasms/drug therapy, Liver Neoplasms/pathology, Male, Microspheres, Polyethylene Glycols/adverse effects, Treatment Outcome

Relation: Journal of Vascular and Interventional Radiology; https://iris.unil.ch/handle/iris/105807; serval:BIB_4BB70DC65E01; 000833350400006

Verfügbarkeit: https://iris.unil.ch/handle/iris/105807
https://doi.org/10.1016/j.jvir.2021.11.019

PEG 3350 Versus Lactulose for Treatment of Functional Constipation in Children: Randomized Study

Autoren: Jaroslaw Kierkus Monika Kowalczuk-Krystoń Maciej Pelc et al.

Quelle: Journal of Pediatric Gastroenterology and Nutrition. 68:318-324

Schlagwörter: Male, Constipation - drug therapy, Administration, Oral, Gastrointestinal agents - administration & dosage, preschool, Gastrointestinal agents - adverse effects, Drug Administration Schedule, Polyethylene Glycols, oral, 03 medical and health sciences, 0302 clinical medicine, Gastrointestinal Agents, Humans, Lactulose - administration & dosage, Child, Defecation, Lactulose - adverse effects, Polyethylene glycols - adverse effects, Drug administration schedule, Lactulose, 3. Good health, Child, Preschool, Administration, Female, Polyethylene glycols - administration & dosage, Defecation - drug effects, Constipation

Zugangs-URL: https://journals.lww.com/jpgn/Fulltext/2019/03000/PEG_3350_Versus_Lactulose_for_Treatment_of.11.aspx
https://pubmed.ncbi.nlm.nih.gov/30383579
https://pubmed.ncbi.nlm.nih.gov/30383579/
https://www.ncbi.nlm.nih.gov/pubmed/30383579
https://insights.ovid.com/pediatric-gastroenterology-nutrition/jpga/2019/03/000/peg-3350-versus-lactulose-treatment-functional/11/00005176

Efficacy and safety of split-dose bowel preparation with 1 L polyethylene glycol and ascorbate compared with 2 L polyethylene glycol and ascorbate in a Korean population: a phase IV, multicenter, randomized, endoscopist-blinded study

Weitere Verfasser: Sung Noh Hong Chang Kyun Lee Jong Pil Im et al.

Schlagwörter: Cathartics* / adverse effects, Colon, Colonoscopy, Humans, Laxatives, Polyethylene Glycols* / adverse effects

Relation: GASTROINTESTINAL ENDOSCOPY; J00920; https://ir.ymlib.yonsei.ac.kr/handle/22282913/191284; https://www.sciencedirect.com/science/article/pii/S001651072101703X?via%3Dihub; T202205353

Verfügbarkeit: https://ir.ymlib.yonsei.ac.kr/handle/22282913/191284
https://doi.org/10.1016/j.gie.2021.09.041
https://www.sciencedirect.com/science/article/pii/S001651072101703X?via%3Dihub

Steroid Allergy: Clinical Features and the Importance of Excipient Testing in a Diagnostic Algorithm

Autoren: Iason Thomas Philip H. Li Ryszard Rutkowski et al.

Quelle: The Journal of Allergy and Clinical Immunology: In Practice. 6:1655-1661

Schlagwörter: Adult, Male, Adrenal cortex hormones - immunology, Drug Compounding, Polyethylene Glycols, Drug Hypersensitivity, Excipients, 03 medical and health sciences, 0302 clinical medicine, Adrenal Cortex Hormones, 80 and over, Prevalence, Respiratory Hypersensitivity, Humans, Diagnostic Errors, Middle aged, Allergens - adverse effects, Drug hypersensitivity - diagnosis, Aged, Skin Tests, Respiratory hypersensitivity - diagnosis, Aged, 80 and over, Polyethylene glycols - adverse effects, Respiratory hypersensitivity - epidemiology, Excipients - adverse effects, Allergens - immunology, Poland - epidemiology, Allergens, Middle Aged, Drug hypersensitivity - epidemiology, 3. Good health, Carboxymethylcellulose sodium - adverse effects, Carboxymethylcellulose Sodium, Female, Poland, Diagnostic errors - prevention & control, Drug compounding, Skin tests, Algorithms

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/29408496
https://www.jaci-inpractice.org/article/S2213-2198(18)30031-X/fulltext
https://www.ncbi.nlm.nih.gov/pubmed/29408496
https://www.sciencedirect.com/science/article/abs/pii/S221321981830031X
https://www.jaci-inpractice.org/article/S2213-2198(18)30031-X/pdf

Hepatitis B Surface Antigen Loss with Tenofovir Disoproxil Fumarate Plus Peginterferon Alfa-2a: Week 120 Analysis

Autoren: R. Mehta Alain Chan Henry Lik-Yuen Chan et al.

Weitere Verfasser: R. Mehta Alain Chan Henry Lik-Yuen Chan et al.

Quelle: Dig Dis Sci

Schlagwörter: Adult, Male, Time Factors, Sustained Virologic Response, chronic - drug therapy, Antiviral agents - administration & dosage, Antiviral agents - adverse effects, Recombinant proteins - adverse effects, Chronic hepatitis B, Antiviral Agents, Hepatitis B surface antigens - blood, Polyethylene Glycols, Hepatitis B, Chronic, Interferon-alpha - adverse effects, Humans, HBsAg seroconversion, Tenofovir - adverse effects, Treatment outcome, Middle aged, Tenofovir, Interferon-alpha - administration & dosage, chronic - virology, Sustained virologic response, Tenofovir - administration & dosage, Hepatitis B Surface Antigens, Polyethylene glycols - adverse effects, Time factors, Interferon-alpha, Drug Synergism, Virological response, Middle Aged, Hepatitis B, Recombinant Proteins, 3. Good health, HBsAg loss, Treatment Outcome, combination - methods, Drug monitoring - methods, Recombinant proteins - administration & dosage, Original Article, Drug Therapy, Combination, Female, Drug therapy, Drug synergism, Drug Monitoring, Polyethylene glycols - administration & dosage

Zugangs-URL: https://europepmc.org/articles/pmc6244971?pdf=render
https://pubmed.ncbi.nlm.nih.gov/30136045
https://link.springer.com/content/pdf/10.1007/s10620-018-5251-9.pdf
https://ir.ymlib.yonsei.ac.kr/handle/22282913/167603
https://link.springer.com/article/10.1007/s10620-018-5251-9/fulltext.html
https://ir.ymlib.yonsei.ac.kr/bitstream/22282913/167603/1/T201805520.pdf
https://pubmed.ncbi.nlm.nih.gov/30136045/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244971
https://hdl.handle.net/11591/394546
https://doi.org/10.1007/s10620-018-5251-9

A randomized, multi-center, open-label, phase III study of once-per-cycle DA-3031, a pegylated G-CSF, in comparison with daily filgrastim in patients receiving TAC chemotherapy for breast cancer

Autoren: I. H. Park Yang Soo Kim S. Park et al.

Weitere Verfasser: I. H. Park Yang Soo Kim S. Park et al.

Quelle: Supportive Care in Cancer. 25:505-511

Schlagwörter: Adult, Neutropenia, Breast Neoplasms / drug therapy, Filgrastim / administration & dosage, Filgrastim, Injections, Subcutaneous, Breast Neoplasms, Filgrastim / adverse effects, Docetaxel, Cyclophosphamide / administration & dosage, Drug Administration Schedule, Injections, Polyethylene Glycols, 03 medical and health sciences, Breast cancer, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols / adverse effects, Antineoplastic Combined Chemotherapy Protocols, Granulocyte Colony-Stimulating Factor, Polyethylene Glycols / adverse effects, Humans, Chemotherapy-Induced Febrile Neutropenia / etiology, Granulocyte Colony-Stimulating Factor / adverse effects, Polyethylene Glycols / administration & dosage, Chemotherapy-Induced Febrile Neutropenia, Cyclophosphamide, Taxoids / administration & dosage, Aged, Subcutaneous, TAC chemotherapy, Chemotherapy-Induced Febrile Neutropenia / drug therapy, Doxorubicin / administration & dosage, Antineoplastic Combined Chemotherapy Protocols / administration & dosage, Middle Aged, 3. Good health, Doxorubicin, Granulocyte Colony-Stimulating Factor / administration & dosage, Female, Taxoids, Chemotherapy-Induced Febrile Neutropenia / prevention & control, Pegylated G-CSF

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/27709313

Different profile of thrombin generation in children with acute lymphoblastic leukaemia treated with native or pegylated asparaginase: A cohort study: Rozen et al.

Autoren: Rozen, Laurence Noubouossié, Denis Dedeken, Laurence et al.

Quelle: Pediatric Blood & Cancer. 64:294-301

Schlagwörter: Male, haemostatic potential, acute lymphoblastic leukaemia, Adolescent, Pédiatrie, Antineoplastic Agents, Precursor Cell Lymphoblastic Leukemia-Lymphoma -- complications -- drug therapy -- metabolism, Polyethylene Glycols, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Polyethylene Glycols -- adverse effects, Asparaginase -- adverse effects, Asparaginase, Humans, coagulation, Preschool, Child, Hemostasis, Thrombosis -- chemically induced -- diagnosis -- metabolism, Thrombin, Antineoplastic Agents -- adverse effects, Infant, Thrombosis, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Thrombin -- metabolism, asparaginase, Prognosis, 3. Good health, Cancérologie, thrombin generation, Child, Preschool, Female, Hématologie, Follow-Up Studies

Dateibeschreibung: 1 full-text file(s): application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/27605400
https://onlinelibrary.wiley.com/doi/abs/10.1002/pbc.26228
https://www.ncbi.nlm.nih.gov/pubmed/27605400
https://difusion.ulb.ac.be/vufind/Record/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/242209/Details

Daclatasvirvstelaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1

Autoren: Jacobson, Ira Zeuzem, Stefan Flisiak, Robert et al.

Quelle: World Journal of Gastroenterology. 22:3418-3431

Schlagwörter: Male, 0301 basic medicine, chronic - drug therapy, Antiviral agents - adverse effects, Recombinant proteins - adverse effects, Hepacivirus, Polyethylene Glycols, 0302 clinical medicine, viral - blood, Interferon-alpha - adverse effects, Viral load, Treatment outcome, Middle aged, Imidazoles - adverse effects, chronic - diagnosis, chronic - virology, Interleukins - genetics, Oligopeptides - adverse effects, Polyethylene glycols - adverse effects, Polyethylene glycols - therapeutic use, Oligopeptides - therapeutic use, Imidazoles, Middle Aged, Hepatitis C, 3. Good health, Drug Therapy, Combination, Female, Drug therapy, Oligopeptides, Adult, Imidazoles - therapeutic use, Adolescent, Genotype, Antiviral agents - therapeutic use, Recombinant proteins - therapeutic use, Antiviral Agents, viral - genetics, Viral nonstructural proteins - antagonists & inhibitors, Interferon-alpha - therapeutic use, 03 medical and health sciences, Chronic hepatitis C, Daclatasvir, Direct-acting antiviral, Genotype 1b, Liver disease, NS5A inhibitor, Aged, Drug Resistance, Viral, Hepatitis C, Chronic, Humans, Interferon-alpha, Interleukins, Polymorphism, Genetic, RNA, Viral, Recombinant Proteins, Ribavirin, Time Factors, Treatment Outcome, Viral Load, Viral Nonstructural Proteins, Young Adult, Gastroenterology, Polymorphism, combination, chronic - genetics, Time factors, Hepacivirus - genetics, Ribavirin - therapeutic use, Young adult, Drug resistance, RNA, Viral nonstructural proteins - genetics, Hepacivirus - drug effects, Carbamates, Interferons, genetic, Ribavirin - adverse effects

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/27022224
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806200/
https://www.wjgnet.com/1007-9327/full/v22/i12/3418.htm
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806200/
https://flore.unifi.it/handle/2158/1084507
http://europepmc.org/articles/PMC4806200
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4806200/table/T3/
https://hdl.handle.net/2158/1084507
http://www.wjgnet.com/1007-9327/mcsy.asp
https://doi.org/10.3748/wjg.v22.i12.3418

mRNA 'vaccine' biodistribution, persistence, and adjuvant toxicity library

Autoren: Sass, Erik

Schlagwörter: mRNA Vaccines, biodistribution, lipid nanoparticles, LNP, Polyethylene Glycols/adverse effects, Spike Glycoprotein, Coronavirus, Coronavirus/blood, Coronavirus/analysis, coronavirus spike protein persistence, vaccine mRNA persistence

Relation: https://zenodo.org/records/14559625; oai:zenodo.org:14559625; https://doi.org/10.5281/zenodo.14559625

Verfügbarkeit: https://doi.org/10.5281/zenodo.14559625
https://zenodo.org/records/14559625

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment‐naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II): alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)

Autoren: Zeuzem, S Flisiak, R Vierling, J. M et al.

Weitere Verfasser: Zeuzem, S Flisiak, R Vierling, J. M et al.

Quelle: Alimentary Pharmacology & Therapeutics. 42:829-844

Schlagwörter: Adult, Male, 0301 basic medicine, Double-blind method, Adolescent, Genotype, chronic - drug therapy, Antiviral agents - administration & dosage, Antiviral agents - adverse effects, Recombinant proteins - adverse effects, Hepacivirus, Antiviral Agents, Polyethylene Glycols, Cyclosporine - adverse effects, 03 medical and health sciences, Double-Blind Method, Interferon-alpha - adverse effects, Ribavirin, Humans, Pharmacology (medical), Treatment outcome, Middle aged, Aged, combination, Interferon-alpha - administration & dosage, Ribavirin - administration & dosage, chronic - virology, Polyethylene glycols - adverse effects, Cyclosporine, Drug Therapy, Combination, Female, Hepatitis C, Chronic, Interferon-alpha, Middle Aged, Recombinant Proteins, Treatment Outcome, United States, Young Adult, Hepatitis C, Hepacivirus - genetics, 3. Good health, Cyclosporine - administration & dosage, Young adult, Recombinant proteins - administration & dosage, Drug therapy, Hepacivirus - drug effects, Polyethylene glycols - administration & dosage, Ribavirin - adverse effects

Dateibeschreibung: application/pdf

Zugangs-URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/apt.13342
https://pubmed.ncbi.nlm.nih.gov/26238707
https://www.ncbi.nlm.nih.gov/pubmed/26238707
https://iris.unipa.it/handle/10447/401609
https://research.birmingham.ac.uk/portal/en/publications/randomised-clinical-trial(e474dae5-6b05-447d-87e4-f5433e0ceb72).html
https://researchportal.vub.be/en/publications/randomised-clinical-trial-alisporivir-combined-with-peginterferon
https://onlinelibrary.wiley.com/doi/10.1111/apt.13342
https://europepmc.org/abstract/MED/26238707
https://hdl.handle.net/11577/3196002
https://doi.org/10.1111/apt.13342
https://hdl.handle.net/10447/401609
https://doi.org/10.1111/apt.13342
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2036
https://biblio.vub.ac.be/vubir/(361ab324-7923-48b1-98e4-af989bb0a437).html
http://hdl.handle.net/10722/227364

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection

Autoren: Ferenci, Peter Morano, Luis Enrique Crespo Garcia, Carlos Javier et al.

Quelle: Ferenci, Peter; Asselah, Tarik; Foster, Graham R; Zeuzem, Stefan; Sarrazin, Christoph; Moreno, Christophe; Ouzan, Denis; Maevskaya, Marina; Calinas, Filipe; Morano, Luis E; Crespo, Javier; Dufour, Jean-François; Bourlière, Marc; Agarwal, Kosh; Forton, Daniel; Schuchmann, Marcus; Zehnter, Elmar; Nishiguchi, Shuhei; Omata, Masao; Kukolj, George; ... (2015). STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. Journal of hepatology, 62(6), pp. 1246-1255. Elsevier 10.1016/j.jhep.2014.12.024 <http://dx.doi.org/10.1016/j.jhep.2014.12.024>

Schlagwörter: Male, 0301 basic medicine, Aminoisobutyric Acids, Recombinant Proteins/administration & dosage, Ribavirin/adverse effects, Polyethylene Glycols/adverse effects, Hepacivirus, Polyethylene Glycols, 0302 clinical medicine, Thiazoles/administration & dosage, Interferon-alpha/adverse effects, Gastro-entérologie, Middle Aged, Antiviral Agents/adverse effects, Recombinant Proteins, 3. Good health, Clinical trial, Quinolines, RNA, Viral, Drug Therapy, Combination, Female, Oligopeptides, Antiviral Agents/administration & dosage, Hepacivirus/classification, Adult, Genotype, Proline, Interferon-alpha/administration & dosage, Hepacivirus/genetics, 610 Medicine & health, Phase 3, Antiviral Agents, Oligopeptides/administration & dosage, 03 medical and health sciences, Early treatment success, Hepatitis C, Chronic/drug therapy, Double-Blind Method, Leucine, Hepatitis C, Chronic/virology, Recombinant Proteins/adverse effects, Humans, RNA, Viral/blood, Polyethylene Glycols/administration & dosage, DAA, Hepacivirus/drug effects, Interferon-alpha, Hepatitis C, Chronic, CHLC GAS, SVR12, Thiazoles/adverse effects, NS3/4A protease inhibitor, Ribavirin/administration & dosage, Oligopeptides/adverse effects

Dateibeschreibung: application/pdf; 1 full-text file(s): application/pdf

Zugangs-URL: http://repositorio.chlc.min-saude.pt/bitstream/10400.17/2513/1/J%20Hepatol%202015.pdf
https://pubmed.ncbi.nlm.nih.gov/25559324
https://www.sciencedirect.com/science/article/pii/S0168827814009532
https://boris.unibe.ch/67159/
https://www.journal-of-hepatology.eu/article/S0168-8278(14)00953-2/fulltext
https://difusion.ulb.ac.be/vufind/Record/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/205713/Details
https://core.ac.uk/display/30697171
https://repositorio.chlc.min-saude.pt/bitstream/10400.17/2513/1/J%20Hepatol%202015.pdf
http://hdl.handle.net/10400.17/2513
https://boris.unibe.ch/67159/